These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 18565259)

  • 1. Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy.
    Rooryck C; Barnetche T; Richez C; Laleye A; Arveiler B; Schaeverbeke T
    Clin Exp Rheumatol; 2008; 26(2):340-2. PubMed ID: 18565259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of variants of Fc gamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti-tumour necrosis factor alpha therapy in rheumatoid arthritis.
    Cañete JD; Suárez B; Hernández MV; Sanmartí R; Rego I; Celis R; Moll C; Pinto JA; Blanco FJ; Lozano F
    Ann Rheum Dis; 2009 Oct; 68(10):1547-52. PubMed ID: 18930989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: a multicenter study.
    Canet LM; Filipescu I; Cáliz R; Lupiañez CB; Canhão H; Escudero A; Segura-Catena J; Soto-Pino MJ; Ferrer MA; García A; Romani L; Pérez-Pampin E; González-Utrilla A; López Nevot MA; Collantes E; Fonseca JE; Sainz J
    Pharmacogenet Genomics; 2015 Jul; 25(7):323-33. PubMed ID: 25850964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
    Kastbom A; Bratt J; Ernestam S; Lampa J; Padyukov L; Söderkvist P; Skogh T
    Arthritis Rheum; 2007 Feb; 56(2):448-52. PubMed ID: 17265480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis.
    Maxwell JR; Potter C; Hyrich KL; ; Barton A; Worthington J; Isaacs JD; Morgan AW; Wilson AG
    Hum Mol Genet; 2008 Nov; 17(22):3532-8. PubMed ID: 18713756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between the TNFRII 196R allele and diagnosis of rheumatoid arthritis.
    Goëb V; Dieudé P; Vittecoq O; Mejjad O; Ménard JF; Thomas M; Gilbert D; Boumier P; Pouplin S; Daragon A; Fardellone P; Tron F; Cornélis F; Le Loët X
    Arthritis Res Ther; 2005; 7(5):R1056-62. PubMed ID: 16207322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study.
    Quartuccio L; Fabris M; Pontarini E; Salvin S; Zabotti A; Benucci M; Manfredi M; Biasi D; Ravagnani V; Atzeni F; Sarzi-Puttini P; Morassi P; Fischetti F; Tomietto P; Bazzichi L; Saracco M; Pellerito R; Cimmino M; Schiavon F; Carraro V; Semeraro A; Caporali R; Cavagna L; Bortolotti R; Paolazzi G; Govoni M; Bombardieri S; De Vita S
    Ann Rheum Dis; 2014 Apr; 73(4):716-21. PubMed ID: 23505228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between the FCGR3A V158F polymorphism and the clinical response to infliximab in rheumatoid arthritis and spondyloarthritis patients.
    Morales-Lara MJ; Conesa-Zamora P; García-Simón MS; Pedrero F; Santaclara V; Perez-Guillermo M; Soriano-Navarro E
    Scand J Rheumatol; 2010 Nov; 39(6):518-20. PubMed ID: 20560817
    [No Abstract]   [Full Text] [Related]  

  • 9. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.
    Potter C; Cordell HJ; Barton A; Daly AK; Hyrich KL; Mann DA; Morgan AW; Wilson AG; ; Isaacs JD
    Ann Rheum Dis; 2010 Jul; 69(7):1315-20. PubMed ID: 20448286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients.
    Martinez A; Salido M; Bonilla G; Pascual-Salcedo D; Fernandez-Arquero M; de Miguel S; Balsa A; de la Concha EG; Fernandez-Gutierrez B
    Arthritis Rheum; 2004 Apr; 50(4):1077-82. PubMed ID: 15077289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.
    Buch MH; Bingham SJ; Bejarano V; Bryer D; White J; Reece R; Quinn M; Emery P
    Arthritis Rheum; 2007 Apr; 57(3):448-53. PubMed ID: 17394231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab therapy in established rheumatoid arthritis: an observational study.
    Voulgari PV; Alamanos Y; Nikas SN; Bougias DV; Temekonidis TI; Drosos AA
    Am J Med; 2005 May; 118(5):515-20. PubMed ID: 15866254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
    Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
    Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
    Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of high levels of soluble tumour necrosis factor-α receptor-2 produced by alternative splicing in rheumatoid arthritis: a longitudinal prospective cohort study.
    Cañete JD; Albaladejo C; Hernández MV; Laínez B; Pinto JA; Ramírez J; López-Armada MJ; Rodríguez-Cros JR; Engel P; Blanco FJ; Sanmartí R
    Rheumatology (Oxford); 2011 Apr; 50(4):721-8. PubMed ID: 21134963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
    Ollendorf DA; Klingman D; Hazard E; Ray S
    Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fcγ receptor IIIb polymorphism and use of glucocorticoids at baseline are associated with infusion reactions to infliximab in patients with rheumatoid arthritis.
    Okuyama A; Nagasawa H; Suzuki K; Kameda H; Kondo H; Amano K; Takeuchi T
    Ann Rheum Dis; 2011 Feb; 70(2):299-304. PubMed ID: 20980704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab.
    Lequerré T; Jouen F; Brazier M; Clayssens S; Klemmer N; Ménard JF; Mejjad O; Daragon A; Tron F; Le Loët X; Vittecoq O
    Rheumatology (Oxford); 2007 Mar; 46(3):446-53. PubMed ID: 16899502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of anti-CCP positivity and carriage of TNFRII susceptibility variant with anti-TNF-α response in rheumatoid arthritis.
    Vasilopoulos Y; Bagiatis V; Stamatopoulou D; Zisopoulos D; Alexiou I; Sarafidou T; Settas L; Sakkas L; Mamouris Z
    Clin Exp Rheumatol; 2011; 29(4):701-4. PubMed ID: 21813066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis.
    Toonen EJ; Coenen MJ; Kievit W; Fransen J; Eijsbouts AM; Scheffer H; Radstake TR; Creemers MC; de Rooij DJ; van Riel PL; Franke B; Barrera P
    Ann Rheum Dis; 2008 Aug; 67(8):1174-7. PubMed ID: 18385279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.